生物制剂时代类风湿关节炎糖皮质激素使用的时间趋势:1999-2018年
该基于人群的起始队列纳入1999-2018年诊断的类风湿关节炎患者,随访至2020年12月31日。1999-2008年诊断的患者中67%在6个月内起始糖皮质激素,2009-2018年诊断的患者中为71%,后者起始风险增加29%(校正HR 1.29,95%CI 1.09-1.53)。两组6个月内停药率相似(39.1% vs 42.9%,校正HR 1.11,95%CI 0.93-1.31,无显著关联)。
要点
- 1999-2008年诊断者67%在6个月内起始糖皮质激素,2009-2018年诊断者为71%。
- 2009-2018年诊断者起始糖皮质激素的风险较1999-2008年诊断者增加29%(校正HR 1.29,95%CI 1.09-1.53)。
- 两组6个月内停药率相似(39.1% vs 42.9%),校正HR 1.11(95%CI 0.93-1.31),无显著关联。
核心结论
- 与既往相比,现在更多患者在疾病早期起始糖皮质激素;尽管已有生物制剂可用,糖皮质激素停药率仍相似。
研究设计与样本
- 基于人群的起始队列,纳入1999-2018年诊断且符合1987年美国风湿病学会分类标准的类风湿关节炎患者,通过病历纵向随访至死亡、迁出或2020年12月31日。
- 研究人群包括1999-2008年诊断的399例患者(女性71%)和2009-2018年诊断的430例患者(女性67%)。
- 收集糖皮质激素起始和停止日期及泼尼松等效剂量,采用竞争风险模型(校正死亡)估计起始和停药的累积发生率,并使用校正年龄和性别的Cox模型比较各时间段趋势。
主要发现
- 1999-2008年诊断的患者中67%在符合类风湿关节炎标准后6个月内起始糖皮质激素,2009-2018年诊断的患者中为71%,对应2009-2018年起始风险增加29%(校正HR 1.29,95%CI 1.09-1.53)。
- 在糖皮质激素使用者中,1999-2008年与2009-2018年诊断的患者在起始后6个月内停药率相似(39.1% vs 42.9%),校正Cox模型无显著关联(HR 1.11,95%CI 0.93-1.31)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To examine time trends in glucocorticoid (GC) use among patients diagnosed with rheumatoid arthritis (RA) during the biologic era. METHODS: A population-based inception cohort of RA patients diagnosed during 1999 - 2018 was followed longitudinally through their medical records until death, migration or 12/31/2020. All patients fulfilled 1987 American College of Rheumatology classification criteria for RA. GC start and stop dates were collected along with dosages in prednisone equivalents. The cumulative incidence of GC initiation and discontinuation adjusted for the competing risk of death was estimated. Cox models adjusted for age and sex were used to compare trends between time periods. RESULTS: The study population included 399 patients (71% female) diagnosed in 1999 - 2008 and 430 patients (67% female) diagnosed in 2009 - 2018. GC use was initiated within 6 months of meeting RA criteria in 67% of patients in 1999-2008 and 71% of patients in 2009-2018, corresponding to a 29% increase in hazard for initiation of GC in 2009-2018 (adjusted hazard ratio [HR]: 1.29; 95% confidence interval [CI]: 1.09-1.53). Among GC users, similar rates of GC discontinuation within 6 months after GC initiation were observed in patients with RA incidence in 1999 - 2008 and 2009 - 2018 (39.1% versus 42.9%, respectively), with no significant association in adjusted Cox models (HR: 1.11; 95% CI: 0.93-1.31). CONCLUSION: More patients are initiating GCs early in their disease course now compared to previously. The rates of GC discontinuation were similar, despite the availability of biologics.
引用
- Crowson LP, Davis JM, Hanson AC, et al. Time Trends in Glucocorticoid Use in Rheumatoid Arthritis During the Biologics Era: 1999-2018. Semin Arthritis Rheum. 2023. PMID: 37172495. doi:10.1016/j.semarthrit.2023.152219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。